Drug
Rsvpref3 OA Investigational Vaccine
Rsvpref3 OA Investigational Vaccine: highest development phase Phase 3, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| RSVPreF3 OA investigational vaccine NCT06551181 | Phase 3 | Respiratory Syncytial Virus Infections |
Latest
No recent events.
Follow Rsvpref3 OA Investigational Vaccine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.